LMNL Key Statistics, Chart & Performance
The current stock price of LMNL is 8.5 USD. In the past month the price increased by 0.9%. In the past year, price increased by 102.38%.
LMNL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.18 | 403.83B | ||
| AMGN | AMGEN INC | 14.97 | 176.25B | ||
| GILD | GILEAD SCIENCES INC | 14.99 | 152.28B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.12 | 115.03B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.15 | 81.12B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 779.71 | 52.53B | ||
| INSM | INSMED INC | N/A | 37.12B | ||
| NTRA | NATERA INC | N/A | 31.62B | ||
| BIIB | BIOGEN INC | 10.51 | 25.82B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.46 | 20.98B | ||
| INCY | INCYTE CORP | 15.38 | 19.39B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About LMNL
Company Profile
Liminal BioSciences, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Belleville, Ontario and currently employs 43 full-time employees. The company went IPO on 2019-07-05. The firm is focused on developing distinctive novel small molecule therapeutics for inflammatory, fibrotic and metabolic diseases using its drug discovery platform. The firm is developing Selective G-protein coupled receptor 84 (GPR84) Antagonist and Oxo-eicosanoid receptor 1 (OXER1) Antagonist. Its GPR84 is a pro-inflammatory target primarily expressed on cells associated with the immune system and its expression levels increase significantly during periods of inflammatory stress. Inhibition of GPR84 can inhibit neutrophil and macrophage migration and reduce cytokine release. GPR84 antagonist program is at the pre-clinical-stage. The OXER1 is a G protein-coupled receptor (GPCR) that is highly selective for 5-Oxo-eicosatetraenoic acid (5-oxo-ETE), a potent human eosinophil chemo-attractant. OXER1 antagonist program is in the pre-clinical-stage.
Company Info
LIMINAL BIOSCIENCES INC
231 Dundas Street East
Belleville ONTARIO H7V 4B4 CA
CEO: Bruce Pritchard
Employees: 43
Phone: 14507810115.0
LIMINAL BIOSCIENCES INC / LMNL FAQ
What does LIMINAL BIOSCIENCES INC do?
Liminal BioSciences, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Belleville, Ontario and currently employs 43 full-time employees. The company went IPO on 2019-07-05. The firm is focused on developing distinctive novel small molecule therapeutics for inflammatory, fibrotic and metabolic diseases using its drug discovery platform. The firm is developing Selective G-protein coupled receptor 84 (GPR84) Antagonist and Oxo-eicosanoid receptor 1 (OXER1) Antagonist. Its GPR84 is a pro-inflammatory target primarily expressed on cells associated with the immune system and its expression levels increase significantly during periods of inflammatory stress. Inhibition of GPR84 can inhibit neutrophil and macrophage migration and reduce cytokine release. GPR84 antagonist program is at the pre-clinical-stage. The OXER1 is a G protein-coupled receptor (GPCR) that is highly selective for 5-Oxo-eicosatetraenoic acid (5-oxo-ETE), a potent human eosinophil chemo-attractant. OXER1 antagonist program is in the pre-clinical-stage.
What is the current price of LMNL stock?
The current stock price of LMNL is 8.5 USD. The price increased by 0.12% in the last trading session.
What is the dividend status of LIMINAL BIOSCIENCES INC?
LMNL does not pay a dividend.
What is the ChartMill technical and fundamental rating of LMNL stock?
LMNL has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Where is LIMINAL BIOSCIENCES INC (LMNL) stock traded?
LMNL stock is listed on the Nasdaq exchange.
How many employees does LIMINAL BIOSCIENCES INC have?
LIMINAL BIOSCIENCES INC (LMNL) currently has 43 employees.
What is the ownership structure of LIMINAL BIOSCIENCES INC (LMNL)?
You can find the ownership structure of LIMINAL BIOSCIENCES INC (LMNL) on the Ownership tab.
LMNL Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to LMNL. When comparing the yearly performance of all stocks, LMNL is one of the better performing stocks in the market, outperforming 98.13% of all stocks.
LMNL Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to LMNL. LMNL may be in some trouble as it scores bad on both profitability and health.
LMNL Financial Highlights
Over the last trailing twelve months LMNL reported a non-GAAP Earnings per Share(EPS) of 0.11. The EPS decreased by -99.1% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 94.11% | ||
| ROA | 1.46% | ||
| ROE | 2.16% | ||
| Debt/Equity | 0.02 |
LMNL Forecast & Estimates
6 analysts have analysed LMNL and the average price target is 7.65 USD. This implies a price decrease of -10% is expected in the next year compared to the current price of 8.5.